Urologic cancer surgeon, @BehfarEhdaieMD from @MSKCancerCenter, the #1 hospital for urology according to @usnews explained the benefits of @FocalOneHIFU, and his patient, John B., shared his personal journey in a recent article. "It was pretty much back to normal right away. No cutting, no stiches, no lying in a hospital bed for days or weeks." - John B. Nearly nine years after being treated with HIFU and avoiding both surgery and radiation, John continues to do well. Read the full story here: mskcc.org/news/high-intensit… #Cancer | #ProstateCancer | #Urology | #RoboticSurgery | #MedTech

CONGRATULATIONS, RUNNERS! You did it! You just completed one of the greatest races in the world. Thank you for your relentless dedication to training and fundraising with us this year. We are so proud of this incredible community. 🫶

Education, Proactive Management Are Key to Navigating Ocular Toxicities and Other ADC-Related AEs in Breast Cancer @jhaveri_komal @MSKCancerCenter #bcsm #oncology onclive.com/view/education-p…

MSK's Department of Surgery is now accepting applications for a one-year International Surgical Oncology Global Cancer Disparities Fellowship to fully trained surgeons. The aim of the fellowship is to train the fellow to effectively direct multimodality cancer therapy for cancer patients in both high- and low-income countries. Learn more and apply here: bit.ly/47sqRwB

Despite undergoing chemotherapy and radiation, Liz Healy is taking on the @nycmarathon this Sunday—her third consecutive year with Fred’s Team. She recently sat down with @ABC7NY to share her story and raise awareness about colorectal cancer. Tune in here. abc7ny.com/videoClip/1807805…

Little progress has been made in the treatment of anaplastic thyroid cancer @VeraTiedje @Gnana_Krish et al. @MSKCancerCenter now find mice with aggressive ATC respond to the inhibitor combination dabrafenib/trametinib by affecting cancer cell MHCII expression & increasing T-cell infiltration. jci.org/articles/view/191781 The image shows multiplex immunofluorescence for immune cell populations in the tumor microenvironment of thyroid cancers.

MSK's Global Cancer Research and Training Program is now accepting applications for the Stern Fellowship in Global Oncology Research. This fellowship is open to current or recently graduated U.S. or Canadian residents and PhD students interested in gaining hands-on experience in global oncology research and developing the skills to collaborate effectively with cancer researchers in low- and middle-income countries. Learn more and apply here: bit.ly/4nFz1b3

"My experience tells me that the best way to tackle the challenges keeping us from curing all cancers in all patients using immunotherapy is through team science," says @andyjminn, the inaugural chair of MSK's Immuno-Oncology Program and co-director of the Marie-Josee Kravis Center for Cancer Immunobiology. "I believe that through this process, we will deliver the hope for meaningful and durable responses to immunotherapy for many more patients — the type of responses the immune system is meant to provide. And I can think of no better place than MSK to do this work of further unlocking immunotherapy’s potential." Learn more about Dr. Minn's vision for the program and what it means for patients: bit.ly/3WYcgUz

🚨The FDA has approved revumenib for patients with R/R AML and a susceptible NPM1 mutation. Read our latest article to learn more and to gain valuable insight into the AUGMENT-101 trial from Eytan Stein (@MSKCancerCenter): 👉 ow.ly/rl1K50XjeOI 👈 #AMLsm #Leusm #Leukemia #CTSM #HemOnc

.@PedramRazaviMD, a physician-scientist at MSK, explains MSK's efforts to prevent drug resistance from developing in #breastcancer patients. “In the past, we’ve always been reactive — we give a treatment, the cancer adapts to survive, and then we give a drug that blocks that path of resistance,” says Dr. Razavi. “But the next line of therapy generally does not work as well as the first. Now we are trying to develop ways to predict the behavior of cancer and stay ahead of it.” A new study seeks to anticipate the malignant cells' next move, like playing poker with cancer and being able to see most of its cards. Learn more: bit.ly/3JzN57N

Join us for @WeillCornell and @MSKCancerCenter's Global Oncology Symposium, featuring a talk by Dr. Lisa Newman (@LANewmanMD) from @WCMSurgery and the @WCMEnglanderIPM, among other terrific speakers! October 30th at 4:00pm, Weill Greenberg Center, WGC-A & B.

@eugene_pietzak of @MSKCancerCenter leads @ALLIANCE_org A032303/GAIN-BCG testing if adding the anti-cancer drug gemcitabine to the standard treatment of BCG immunotherapy helps patients whose non-invasive bladder cancer has come back. Learn more: bit.ly/Alliance-A032303

Protection against the fungus among us after mold spore inhalation… Tobias M. Hohl @tmhohl71 & team @MSKCancerCenter investigate Aspergillus fumigatus infection in mice, revealing communication between plasmacytoid DCs and neutrophils in the lung is necessary for antifungal activity. jci.org/articles/view/190107

Privileged to Learn from Experts Who Set the Standard in Cancer Care and Research - Rixci Ramírez @MSKCancerCenter oncodaily.com/voices/rixci-r… #Cancer #Medicine #Health #Oncology #OncoDaily #MedX #MedNews #MedEd #Cancercare #CancerResearch

📢 DON'T MISS: T-CELL LYMPHOMA EXPERT IN-PERSON! 📢 Listen to Dr. Jasmine M. Zain from @MSKCancerCenter Memorial Sloan Kettering, USA! A leading Lymphoma Specialist presenting IN-PERSON. Topic: How I sequence treatment of T cell lymphoma. 🗓️ When: Friday, 7th November 2025 at 2035 PKT FREE Registration Link: NIBMTevents.com This is a must-attend session for the latest sequencing strategies! 👆 #PBMT #PSH #NIBMT #ASH2024 #ASCO2025 #EHA2025 #DrJasmineZain #Lymphoma #OncologyUpdate

The final session of #iwHRMM25 is underway! Maximilian Merz of @MSKCancerCenter is discussing the importance of translational studies in clinical trials of HRMM.🔎 #MMSM #MultipleMyeloma #Myeloma #HemOnc #CTSM

What’s new in #breastpathology? @HannahYWen of @MSKCancerCenter kicks off the #LSBC25 afternoon session with insights on “The Ever-Changing Field of Breast Tumor #Biomarkers.” #BreastPath

🔎🧬 Kylee MacLachlan of @MSKCancerCenter provides insight into the prognostic impact of t(4;14), alone and in combination with other genomic risk factors. #iwHRMM25 #MMSM #MultipleMyeloma #Myeloma #HemOnc

MSK experts are investigating whether #brachytherapy may be an effective treatment option for reducing local recurrence, lowering the risk of #necrosis associated with standard #radiation, and improving the quality of life for patients with brain #metastases. “Brachytherapy is an important tool in our toolbox, but it is one of many options we provide within our multidisciplinary program.” Learn more: bit.ly/4ng4IqT

How do we address the unique challenges facing adolescent and young adult cancer patients? Find out in our latest article, which outlines ethical frameworks for different age subsets. hubs.ly/Q03Pr6J30 #AYAOncology @MSKCancerCenter)